ArticleFrontiers in immunology2019

Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition.

Lei Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.